BTLA and B-cell chronic lymphocytic leukemia: In summary, this study indicates that immunotherapy approaches based on systemic administration of anti-miR-155-5p therapeutics would be a favorable strategy in CLL, since it does not affect BTLA expression in the T cell population and may benefit CLL patients with impaired BTLA levels on CLL cells.